Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation

Cardiovascular Therapeutics

Volumn 32, Issue 2, 2014, Pages 74-81

  Deitelzweig, Steven ^a,b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; REVIEW;

APIXABAN; ATRIAL FIBRILLATION; DABIGATRAN; RIVAROXABAN; STROKE PREVENTION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; HEMORRHAGE; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84896069720     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12048     Document Type: Review

References (68)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
2. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049-1056.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-2375.
4. Hannon N, Sheehan O, Kelly L, et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 2010;29:43-49.
5. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation-a 21-year community-based study. J Am Coll Cardiol 2007;49:986-992.
6. Penado S, Cano M, Acha O, Hernández JL, Riancho JA. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med 2003;114:206-210.
7. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002;113:365-370.
8. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley Study. Am J Med 2002;113:359-364.
9. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952.
10. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
11. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-e354.
12. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S-198S.
13. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
14. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126:1938-1945.
15. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91.
16. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457. Erratum in Arch Intern Med 1994;154:2254.
17. Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008;39:7-9.
18. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-252.
19. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006;97:538-543.
20. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:1070-1074.
21. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010;3:624-631.
22. De Schryver EL, van Gijn J, Kappelle LJ, et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005;252:1316-1321.
23. You J, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl.):e531S-e575S.
24. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-1166.
25. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA 2003;290:2685-2692.
26. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009;40:235-240.
27. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011;40:675-683.
28. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22.
29. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2013.
30. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
31. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-753.
32. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011.
33. Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb and New York, NY: Pfizer Inc.; 2012.
34. Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 1996;30:300-313.
35. European Medicines Agency. CHMP Assessment report for Xarelto. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/000944/WC500057122.pdf. Accessed June 13, 2012.
36. Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor. Drugs 2011;71:1503-1526.
37. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Absolute bioavailability of edoxaban in healthy subjects. AAPS J 2011;13(Suppl. 2):T2362.
38. Masumoto H, Yoshigae Y, Watanabe K, et al. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban [abstr]. AAPS J 2010;12(Suppl. 2):W4308.
39. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641e2.
40. Bathala M, Masumoto H, Oguma T, Mendell J. Biotransformation of edoxaban after oral administration to humans [abstr]. AAPS J 2010;12(Suppl. 2):W4264.
41. Mendell J, Zahir H, Ridout G, et al. Drug-drug interaction studies for cardiovascular drugs (amiodarone, digoxin, quinidine, atorvastatin and verapamil) involving P-glycoprotein (P-GP), and efflux transporter, on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban, an oral factor Xa inhibitor [abstr]. J Am Coll Cardiol 2011;57(14 Suppl.):E1510.
42. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. Erratum in N Engl J Med 2010; 363:1877.
43. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.
44. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
45. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
46. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.
47. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-698.
48. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl.):257S-298S.
49. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012;14:8-27.
50. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013;11:245-252.
51. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011;32:183-187.
52. Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010;104:1078-1079.
53. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104:1263-1271.
54. Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006;62:527-537.
55. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-143.
56. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6:820-829.
57. Alikhan R, Rayment R, Keeling D, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 2013. [Epub ahead of print].
58. Johnson and Johnson Pharmaceutical Research and Development, LLC. Advisory Committee Briefing Book. Rivaroxaban for the Prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Patients Undergoing Hip or Knee Replacement Surgery. February 12, 2009. Document number EDMS-PSDB-9099123:2.0. Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM138385.pdf. Accessed August 16, 2013.
59. Zhang D, Frost CE, He K, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos 2013;41:906-915.
60. Wang X, Tirucherai G, Pannacciulli N, et al. Effect of activated charcoal on the pharmacokinetics of apixaban in healthy subjects. Clin Pharmacol Ther 2012;91(Suppl.):S41. Abstract PI-90.
61. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-1579.
62. Escolar G, Arellano-Rodrigo E, Reverter JC, et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation 2012;126:520-521.
63. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-2830.
64. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-2394.
65. Bristol-Myers Squibb/Pfizer EEIG. Eliquis (apixiban). EU summary of product characteristics. Middlesex, UK: Bristol-Myers Squibb/Pfizer EEIG, 2011.
66. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. J Med Econ 2012;15:776-785.
67. Granger CB, Alexander JH, Hanna M, et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J 2012;33(abstr suppl):685-686.
68. Connolly SJ, Reilly PA, Pogue J. Randomized comparison of the effects of two doses of dabigatran etexilate on clinical outcomes over 4.3 years: results of the Rely-able double-blind randomized trial. Abstract presented at: Annual meeting of the American Heart Association; November 4-7, 2012; Los Angeles, CA.